Andrew T. Stefka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew T. Stefka has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej J. Jakubowiak
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL
7 shared publications - Benjamin A. Derman
University of Chicago, Chicago, IL
5 shared publications - Cathryn R. Nagler
Pritzker School of Molecular Engineering, The University of Chicago, Chicago, Illinois, USA
5 shared publications - Tadeusz Kubicki
Section of Hematology/Oncology, University of Chicago, Chicago, USA
3 shared publications Taylor Feehley
Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA
3 shared publications- Ajay Major
Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, USA
2 shared publications
Latest Publications
- Open Access
- 14 November 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-13
Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients
Surgery remains the primary treatment modality in the management of early-stage invasive breast cancer. Artificial intelligence (AI)-powered visualization platforms offer the compelling potential to aid surgeons in evaluating the tumor’s location and morphology within the breast and accordingly optimize their surgical approach. We sought to validate an AI platform that employs dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to render three-dimensional (3D) representations of the tumor and 5 additional chest tissues, offering clear visualizations as well as functionalities for quantifying tumor morphology, tumor-to-landmark structure distances, excision volumes, and approximate surgical margins. This retrospective study assessed the visualization platform’s performance on 100 cases with ground-truth labels vetted by 2 breast-specialized radiologists. We assessed features including automatic AI-generated clinical metrics (e.g., tumor dimensions) as well as visualization tools including convex hulls at desired margins around the tumor to help visualize lumpectomy volume. The statistical performance of the platform’s automated features was robust and within the range of inter-radiologist variability. These detailed 3D tumor and surrounding multi-tissue depictions offer both qualitative and quantitative comprehension of cancer topology and may aid in formulating an optimal surgical approach for breast cancer treatment. We further establish the framework for broader data integration into the platform to enhance precision cancer care.
- 14 November 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-13
Open AccessPerformance of an AI-powered visualization software platform for precision surgery in breast cancer patients
Surgery remains the primary treatment modality in the management of early-stage invasive breast cancer. Artificial intelligence (AI)-powered visualization platforms offer the compelling potential to aid surgeons in evaluating the tumor’s location and morphology within the breast and accordingly optimize their surgical approach. We sought to validate an AI platform that employs dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to render three-dimensional (3D) representations of the tumor and 5 additional chest tissues, offering clear visualizations as well as functionalities for quantifying tumor morphology, tumor-to-landmark structure distances, excision volumes, and approximate surgical margins. This retrospective study assessed the visualization platform’s performance on 100 cases with ground-truth labels vetted by 2 breast-specialized radiologists. We assessed features including automatic AI-generated clinical metrics (e.g., tumor dimensions) as well as visualization tools including convex hulls at desired margins around the tumor to help visualize lumpectomy volume. The statistical performance of the platform’s automated features was robust and within the range of inter-radiologist variability. These detailed 3D tumor and surrounding multi-tissue depictions offer both qualitative and quantitative comprehension of cancer topology and may aid in formulating an optimal surgical approach for breast cancer treatment. We further establish the framework for broader data integration into the platform to enhance precision cancer care.
- Open Access
- 27 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5703-5712
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
We conducted a phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) and KPd with daratumumab (Dara-KPd) in relapsed/refractory multiple myeloma. The primary end points were identification of a maximum tolerated dose (MTD) of KPd for phase 1, and rates of overall response (ORR) and near complete response (nCR) after 4 cycles of KPd and Dara-KPd, respectively, for phase 2. The MTD for KPd was carfilzomib 20/27 mg/m2 on days 1, 2, 8, 9, 15, and 16 (cycles 1-8) and days 1, 2, 15, and 16 for cycles 9 and beyond; oral pomalidomide 4 mg on days 1 to 21; and oral dexamethasone 40 mg weekly in 28-day cycles. Sixty-six patients received KPd, including 34 at the MTD. The ORR after 4 cycles of KPd at the MTD was 27/34 (79%; 95% confidence interval [CI], 62%-91%), meeting the statistical threshold for efficacy. At a median follow-up of 44 months, the median progression-free survival (PFS) was 13 months and overall survival (OS) 44 months. Twenty-eight patients received Dara-KPd. The rate of nCR or better after 4 cycles was 11/28 (39%; 95% CI, 22%-59%), meeting the statistical threshold for efficacy. As the best response to Dara-KPd, the ORR was 25/28 (89%) and the rate of measurable residual disease negativity by flow cytometry (10−5) was 17/26 (65%). At a median follow-up of 26 months, the median PFS and OS for Dara-KPd were not reached. Dara-KPd induced deeper and more durable responses than KPd without compromising safety in a predominantly high-risk, lenalidomide-refractory population, warranting further evaluation of this quadruplet. This trial is registered at www.clinicaltrials.gov as #NCT01665794.
- 27 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5703-5712
Open AccessPhase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
We conducted a phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) and KPd with daratumumab (Dara-KPd) in relapsed/refractory multiple myeloma. The primary end points were identification of a maximum tolerated dose (MTD) of KPd for phase 1, and rates of overall response (ORR) and near complete response (nCR) after 4 cycles of KPd and Dara-KPd, respectively, for phase 2. The MTD for KPd was carfilzomib 20/27 mg/m2 on days 1, 2, 8, 9, 15, and 16 (cycles 1-8) and days 1, 2, 15, and 16 for cycles 9 and beyond; oral pomalidomide 4 mg on days 1 to 21; and oral dexamethasone 40 mg weekly in 28-day cycles. Sixty-six patients received KPd, including 34 at the MTD. The ORR after 4 cycles of KPd at the MTD was 27/34 (79%; 95% confidence interval [CI], 62%-91%), meeting the statistical threshold for efficacy. At a median follow-up of 44 months, the median progression-free survival (PFS) was 13 months and overall survival (OS) 44 months. Twenty-eight patients received Dara-KPd. The rate of nCR or better after 4 cycles was 11/28 (39%; 95% CI, 22%-59%), meeting the statistical threshold for efficacy. As the best response to Dara-KPd, the ORR was 25/28 (89%) and the rate of measurable residual disease negativity by flow cytometry (10−5) was 17/26 (65%). At a median follow-up of 26 months, the median PFS and OS for Dara-KPd were not reached. Dara-KPd induced deeper and more durable responses than KPd without compromising safety in a predominantly high-risk, lenalidomide-refractory population, warranting further evaluation of this quadruplet. This trial is registered at www.clinicaltrials.gov as #NCT01665794.
- Open Access
- 10 September 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (5) , 792-802
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
Summary: Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B‐cell sequences in patients enrolled in the phase 3 ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone (KRd) or lenalidomide (R) maintenance. In the KRd arm, standard‐risk patients with minimal residual disease negativity after six cycles de‐escalated to R alone after cycle 8. One year from the initiation of maintenance at least partial recovery of polyclonal immunoglobulin was observed in more patients on the R arm (58/66, p < 0.001) and in those who de‐escalated from KRd to R (27/38, p < 0.001) compared to the KRd arm (9/36). In patients who switched from KRd to R, the concentrations of uninvolved immunoglobulin and the number of B‐cell unique sequences increased over time, approaching values observed in the R arm. There were no differences in progression‐free survival between the patients with at least partial immunoglobulin recovery and the remaining population. Our analysis indicates that patients receiving continuous therapy after ASCT experience prolonged immunoparesis, limiting prognostic significance of polyclonal immunoglobulin recovery in this setting.
- 10 September 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (5) , 792-802
Open AccessPolyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
Summary: Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B‐cell sequences in patients enrolled in the phase 3 ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone (KRd) or lenalidomide (R) maintenance. In the KRd arm, standard‐risk patients with minimal residual disease negativity after six cycles de‐escalated to R alone after cycle 8. One year from the initiation of maintenance at least partial recovery of polyclonal immunoglobulin was observed in more patients on the R arm (58/66, p < 0.001) and in those who de‐escalated from KRd to R (27/38, p < 0.001) compared to the KRd arm (9/36). In patients who switched from KRd to R, the concentrations of uninvolved immunoglobulin and the number of B‐cell unique sequences increased over time, approaching values observed in the R arm. There were no differences in progression‐free survival between the patients with at least partial immunoglobulin recovery and the remaining population. Our analysis indicates that patients receiving continuous therapy after ASCT experience prolonged immunoparesis, limiting prognostic significance of polyclonal immunoglobulin recovery in this setting.
- Open Access
- 15 February 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (5) , 564-570
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) of wSKd. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Prior exposure/refractoriness to carfilzomib was permitted. Thirty patients were enrolled; 26 (87%) had triple-class exposed disease and 6 (20%) received chimeric antigen receptor (CAR) T-cell therapy. Dose level 2 (carfilzomib 70 mg/m(2) Intravenous [IV] on Days 1, 8, and 15; selinexor 100 mg PO on Days 1, 8, 15, 22; dexamethasone 40 mg on Days 1, 8, 15, 22 of 28-day cycles) was chosen as the MTD, with no DLTs having occurred. The most common hematologic adverse events (AE) were thrombocytopenia (83%), anemia (70%), lymphopenia (50%), and neutropenia (50%). The most common nonhematologic AE were fatigue (70%), nausea (70%), diarrhea (53%), and anorexia (47%). The ORR was 21/30 (70%) overall and 18/23 (78%) at the MTD. At a median follow-up of 12.3 months, the median PFS was 5.3 months and median OS 23.3 months. Responses were similar in carfilzomib naive and exposed patients. Long-term efficacy of wSKd is modest; wSKd could be employed as a bridging strategy to immunotherapies.
- 15 February 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (5) , 564-570
Open AccessA phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) of wSKd. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Prior exposure/refractoriness to carfilzomib was permitted. Thirty patients were enrolled; 26 (87%) had triple-class exposed disease and 6 (20%) received chimeric antigen receptor (CAR) T-cell therapy. Dose level 2 (carfilzomib 70 mg/m(2) Intravenous [IV] on Days 1, 8, and 15; selinexor 100 mg PO on Days 1, 8, 15, 22; dexamethasone 40 mg on Days 1, 8, 15, 22 of 28-day cycles) was chosen as the MTD, with no DLTs having occurred. The most common hematologic adverse events (AE) were thrombocytopenia (83%), anemia (70%), lymphopenia (50%), and neutropenia (50%). The most common nonhematologic AE were fatigue (70%), nausea (70%), diarrhea (53%), and anorexia (47%). The ORR was 21/30 (70%) overall and 18/23 (78%) at the MTD. At a median follow-up of 12.3 months, the median PFS was 5.3 months and median OS 23.3 months. Responses were similar in carfilzomib naive and exposed patients. Long-term efficacy of wSKd is modest; wSKd could be employed as a bridging strategy to immunotherapies.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2759
A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Introduction: The combination of carfilzomib, lenalidomide, and dexamethasone (KRd), with and without autologous stem cell transplantation (ASCT) is an effective regimen for newly diagnosed multiple myeloma (NDMM) (Jakubowiak et al., Blood 2012 and Jasielec et al., Blood 2020). The addition of daratumumab to KRd (Dara-KRd) for 8 cycles led to a measurable residual disease (MRD)-negativity rate of 71% (flow cytometry, limit of detection [LoD] 75) for cycles 1-9, and 20 mg PO weekly for cycles 9-24. ASCT-eligible pts had the option to harvest stem cells to permit ASCT in the future if desired. All subjects undergo testing for MRD using NGS (clonoSEQ, Adaptive Biotechnologies) with a lower LoD of < 10 -6 at the end of cycles 8 (C8) and 24 (C24). The primary endpoint is the rate of stringent CR and/or MRD-negativity (sensitivity threshold 50% with Dara-KRd (85% power using a one-sided alpha=0.10). Results: Of the 29 pts who have been enrolled from March 2019- July 2021, 18 (62%) are evaluable at the C8 timepoint and of which 7/18 are evaluable at C24 by intention-to-treat analysis. The remaining 11 pts are on therapy but have not yet reached C8. 19 pts have an identifiable clone to enable MRD testing by NGS (one sequencing failure, one not performed, eight tests pending). Median age is 57 years (range 42-79; 5 pts >70 years of age). Eight (28%) pts identify their race as Black and 5 (17%) as Hispanic ethnicity. High-risk cytogenetics (per IMWG criteria) is present in 16/29 (55%). 18 pts (62%) have undergone stem cell collection; median stem cell yield is 8.06x10 6 CD34+/kg. For the 18 pts evaluable for the primary endpoint at C8, the overall response rate is 94% (13 sCR, 4 VGPR, 1 PD) (Figure 1). There are 13 MRD-evaluable pts at C8; the sCR and/or MRD-negativity rate (-5) is 13/18 (72%). The sCR+MRD-negativity rate by NGS (10 -5 threshold) is 7/13 (54%) and 3/13 (23%) at a threshold of 10 -6. Responses deepened over time; 4/9 (56%) pts converted from MRD-positive at C8 to MRD-negative (10 -6 threshold) at either C12 or C24. One patient withdrew from the study after C12 to pursue ASCT (VGPR at time of withdrawal). One patient had primary refractory disease after one cycle of therapy and subsequently died from disease progression and CNS involvement. Grade 3+ leukopenia and thrombocytopenia occurred in 21% and 24%, respectively; notable grade 3+ nonhematologic adverse events were hypertension (14%) and a single case of thrombotic microangiopathy leading to discontinuation of carfilzomib. There were no other grade 3 cardiovascular toxicities. Conclusions: The combination of Dara-KRd as extended frontline therapy for NDMM without employing ASCT can induce high rates of MRD-negativity within 8 cycles, exceeding the historical sCR rate of KRd without Dara. Importantly, the rate and depth of MRD-negativity improve beyond cycle 8, suggesting that extended Dara-KRd without ASCT may generate rates of sCR and MRD-negativity comparable to KRd with ASCT. Yearly longitudinal determinations of MRD after completion of 24 cycles of Dara-KRD protocol treatment will generate information on the durability of MRD and the role of ASCT compared to shorter treatments with Dara-KRd, with and without ASCT.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2759
Open AccessA Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Introduction: The combination of carfilzomib, lenalidomide, and dexamethasone (KRd), with and without autologous stem cell transplantation (ASCT) is an effective regimen for newly diagnosed multiple myeloma (NDMM) (Jakubowiak et al., Blood 2012 and Jasielec et al., Blood 2020). The addition of daratumumab to KRd (Dara-KRd) for 8 cycles led to a measurable residual disease (MRD)-negativity rate of 71% (flow cytometry, limit of detection [LoD] 75) for cycles 1-9, and 20 mg PO weekly for cycles 9-24. ASCT-eligible pts had the option to harvest stem cells to permit ASCT in the future if desired. All subjects undergo testing for MRD using NGS (clonoSEQ, Adaptive Biotechnologies) with a lower LoD of < 10 -6 at the end of cycles 8 (C8) and 24 (C24). The primary endpoint is the rate of stringent CR and/or MRD-negativity (sensitivity threshold 50% with Dara-KRd (85% power using a one-sided alpha=0.10). Results: Of the 29 pts who have been enrolled from March 2019- July 2021, 18 (62%) are evaluable at the C8 timepoint and of which 7/18 are evaluable at C24 by intention-to-treat analysis. The remaining 11 pts are on therapy but have not yet reached C8. 19 pts have an identifiable clone to enable MRD testing by NGS (one sequencing failure, one not performed, eight tests pending). Median age is 57 years (range 42-79; 5 pts >70 years of age). Eight (28%) pts identify their race as Black and 5 (17%) as Hispanic ethnicity. High-risk cytogenetics (per IMWG criteria) is present in 16/29 (55%). 18 pts (62%) have undergone stem cell collection; median stem cell yield is 8.06x10 6 CD34+/kg. For the 18 pts evaluable for the primary endpoint at C8, the overall response rate is 94% (13 sCR, 4 VGPR, 1 PD) (Figure 1). There are 13 MRD-evaluable pts at C8; the sCR and/or MRD-negativity rate (-5) is 13/18 (72%). The sCR+MRD-negativity rate by NGS (10 -5 threshold) is 7/13 (54%) and 3/13 (23%) at a threshold of 10 -6. Responses deepened over time; 4/9 (56%) pts converted from MRD-positive at C8 to MRD-negative (10 -6 threshold) at either C12 or C24. One patient withdrew from the study after C12 to pursue ASCT (VGPR at time of withdrawal). One patient had primary refractory disease after one cycle of therapy and subsequently died from disease progression and CNS involvement. Grade 3+ leukopenia and thrombocytopenia occurred in 21% and 24%, respectively; notable grade 3+ nonhematologic adverse events were hypertension (14%) and a single case of thrombotic microangiopathy leading to discontinuation of carfilzomib. There were no other grade 3 cardiovascular toxicities. Conclusions: The combination of Dara-KRd as extended frontline therapy for NDMM without employing ASCT can induce high rates of MRD-negativity within 8 cycles, exceeding the historical sCR rate of KRd without Dara. Importantly, the rate and depth of MRD-negativity improve beyond cycle 8, suggesting that extended Dara-KRd without ASCT may generate rates of sCR and MRD-negativity comparable to KRd with ASCT. Yearly longitudinal determinations of MRD after completion of 24 cycles of Dara-KRD protocol treatment will generate information on the durability of MRD and the role of ASCT compared to shorter treatments with Dara-KRd, with and without ASCT.
- Open Access
- 5 February 2021
- Published by Springer Nature in Blood Cancer Journal
- Vol. 11 (2) , 1-4
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
- 5 February 2021
- Published by Springer Nature in Blood Cancer Journal
- Vol. 11 (2) , 1-4
Open AccessMeasurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
- Open Access
- 26 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (22) , 2513-2523
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10−5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971.
- 26 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (22) , 2513-2523
Open AccessCarfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10−5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971.
- Open Access
- 12 November 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (1) , 324-334
Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
Multiple myeloma (MM) continues to be considered incurable, necessitating new drug discovery. The mitotic kinase T‐LAK cell‐originated protein kinase/PDZ‐binding kinase (TOPK/PBK) is associated with proliferation of tumor cells, maintenance of cancer stem cells, and poor patient prognosis in many cancers. In this report, we demonstrate potent anti‐myeloma effects of the TOPK inhibitor OTS514 for the first time. OTS514 induces cell cycle arrest and apoptosis at nanomolar concentrations in a series of human myeloma cell lines (HMCL) and prevents outgrowth of a putative CD138+ stem cell population from MM patient‐derived peripheral blood mononuclear cells. In bone marrow cells from MM patients, OTS514 treatment exhibited preferential killing of the malignant CD138+ plasma cells compared with the CD138− compartment. In an aggressive mouse xenograft model, OTS964 given orally at 100 mg/kg 5 days per week was well tolerated and reduced tumor size by 48%‐81% compared to control depending on the initial graft size. FOXO3 and its transcriptional targets CDKN1A (p21) and CDKN1B (p27) were elevated and apoptosis was induced with OTS514 treatment of HMCLs. TOPK inhibition also induced loss of FOXM1 and disrupted AKT, p38 MAPK, and NF‐κB signaling. The effects of OTS514 were independent of p53 mutation or deletion status. Combination treatment of HMCLs with OTS514 and lenalidomide produced synergistic effects, providing a rationale for the evaluation of TOPK inhibition in existing myeloma treatment regimens.
- 12 November 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (1) , 324-334
Open AccessPotent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
Multiple myeloma (MM) continues to be considered incurable, necessitating new drug discovery. The mitotic kinase T‐LAK cell‐originated protein kinase/PDZ‐binding kinase (TOPK/PBK) is associated with proliferation of tumor cells, maintenance of cancer stem cells, and poor patient prognosis in many cancers. In this report, we demonstrate potent anti‐myeloma effects of the TOPK inhibitor OTS514 for the first time. OTS514 induces cell cycle arrest and apoptosis at nanomolar concentrations in a series of human myeloma cell lines (HMCL) and prevents outgrowth of a putative CD138+ stem cell population from MM patient‐derived peripheral blood mononuclear cells. In bone marrow cells from MM patients, OTS514 treatment exhibited preferential killing of the malignant CD138+ plasma cells compared with the CD138− compartment. In an aggressive mouse xenograft model, OTS964 given orally at 100 mg/kg 5 days per week was well tolerated and reduced tumor size by 48%‐81% compared to control depending on the initial graft size. FOXO3 and its transcriptional targets CDKN1A (p21) and CDKN1B (p27) were elevated and apoptosis was induced with OTS514 treatment of HMCLs. TOPK inhibition also induced loss of FOXM1 and disrupted AKT, p38 MAPK, and NF‐κB signaling. The effects of OTS514 were independent of p53 mutation or deletion status. Combination treatment of HMCLs with OTS514 and lenalidomide produced synergistic effects, providing a rationale for the evaluation of TOPK inhibition in existing myeloma treatment regimens.
- 21 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6335) , 315-319
Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens
Gut anaerobes protect against pathogen invasion: Intestinal infections are a common problem for young animals. One explanation is that the protective gut microbiota is not fully established in infants. How the microbiota might protect against pathogens is unclear. Kim et al. found that members of the group of strictly anaerobic, spore-forming bacteria known as clostridia protect neonatal mice against diarrhea-causing pathogens. The protective effect is enhanced by giving mice the metabolite succinate in drinking water. Succinate favors colonization of the neonatal gut by cluster IV and XIVa clostridia and concomitantly excludes Salmonella typhimurium. Science , this issue p. 315
- 21 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6335) , 315-319
Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens
Gut anaerobes protect against pathogen invasion: Intestinal infections are a common problem for young animals. One explanation is that the protective gut microbiota is not fully established in infants. How the microbiota might protect against pathogens is unclear. Kim et al. found that members of the group of strictly anaerobic, spore-forming bacteria known as clostridia protect neonatal mice against diarrhea-causing pathogens. The protective effect is enhanced by giving mice the metabolite succinate in drinking water. Succinate favors colonization of the neonatal gut by cluster IV and XIVa clostridia and concomitantly excludes Salmonella typhimurium. Science , this issue p. 315
- Open Access
- 19 August 2016
- Published by Springer Nature in Blood Cancer Journal
- Vol. 6 (8) , e460
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells
- 19 August 2016
- Published by Springer Nature in Blood Cancer Journal
- Vol. 6 (8) , e460
Open AccessAnti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells